VGValeria Giandomenico

Valeria Giandomenico

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valeria Giandomenico has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Kjell Öberg

    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Magnus Essand

    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Ahmed Essaghir

    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    1 shared publication
  • C Hellberg

    Ludwig Institute for Cancer Research, Uppsala, Sweden 4

    1 shared publication
  • George Vasmatzis

    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    1 shared publication
  • J Grawé

    Department of Genetics and Pathology, 2

    1 shared publication

Latest Publications

  • Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

    by Justyna Leja, Ahmed Essaghir, Magnus Essand, Kenneth Wester, Kjell Öberg, Thomas H Tötterman, Ricardo Lloyd, George Vasmatzis, Jean-Baptiste Demoulin, Valeria Giandomenico


  • Open Access

    Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1

    by M Essand, S Vikman, J Grawé, L Gedda, C Hellberg, K Oberg, T H Totterman, V Giandomenico

    Vesicular monoamine transporter 1 (VMAT1) is an integral protein in the membrane of secretory vesicles of neuroendocrine and endocrine cells that allows the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles. The full-length VMAT1 transcript is produced from 16 exons. We have identified and characterized an alternatively spliced form of VMAT1 that lacks exon 15, the next to last exon of VMAT1. The new form was therefore denoted VMAT1Δ15. Exon 15 does not contain an even multiple of three nucleotides. As a consequence, there is a shift of reading frame, and exon 16 is translated in an alternative reading frame, yielding a novel protein with a shorter and unrelated C-terminus compared with the native VMAT1 protein. VMAT1 and VMAT1Δ15 mRNAs are simultaneously expressed in normal and neoplastic neuroendocrine cells of the GI tract. However, VMAT1 expression is always higher than VMAT1Δ15 expression. We prove that VMAT1Δ15 is not localized in large, dense core vesicles as the native form but in the endoplasmic reticulum. Furthermore, while VMAT1 can take up serotonin, VMAT1Δ15 cannot, indicating different functions for the two forms of VMAT1.


  • Open Access

    Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy

    by Sofia Vikman, Magnus Essand, Janet L. Cunningham, Manuel de la Torre, Kjell Öberg, Thomas H. Tötterman, Valeria Giandomenico

    Classical midgut carcinoids are serotonin-secreting tumors derived from enterochromaffin cells in the gut. Metastatic disease represents a therapeutic challenge and immunotherapy implies a novel approach for treatment. In order to define antigens suitable for T-cell therapy with a preferential expression in midgut carcinoid tissue a broad screening of genes with preferential neuroendocrine restriction, genes described as over-expressed in various malignancies, and genes encoding cancer-testis associated antigens was performed. The expression of 32 genes was analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 28 midgut carcinoid specimens, in the cell line BON and in normal tissues. Immunohistochemistry (IHC) was used to evaluate protein expression. Expression is shown of genes that have previously not been observed in midgut carcinoid tumors, such as Survivin and GAGEs. Also the expression is confirmed of genes that encode pivotal proteins in enterochromaffin cells, such as TPH1 and VMAT1, and their tissue-restricted expression is indicated. In addition, gene expression of IA-2 and CDX-2 in normal gastrointestinal (GI) tract and in tumor is shown. Protein expression of TPH, VMAT1, and Survivin was detected in tumor tissue. This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids.